CoChat

Prions activate a p38 MAPK synaptotoxic signaling pathway

Open access
Fang, Cheng, Wu, Bei, Le, Nhat T. T., Imberdis, Thibaut, Mercer, Robert C. C., Harris, David A. · 2018 · PLOS Pathogens
Cited by 72

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Synaptic degeneration is one of the earliest pathological correlates of prion disease, and it is a major determinant of the progression of clinical symptoms. However, the cellular and molecular mechanisms underlying prion synaptotoxicity are poorly understood. Previously, we described an experimental system in which treatment of cultured hippocampal neurons with purified PrPSc, the infectious form of the prion protein, induces rapid retraction of dendritic spines, an effect that is entirely dependent on expression of endogenous PrPC by the target neurons. Here, we use this system to dissect pharmacologically the underlying cellular and molecular mechanisms. We show that PrPSc initiates a stepwise synaptotoxic signaling cascade that includes activation of NMDA receptors, calcium influx, stimulation of p38 MAPK and several downstream kinases, and collapse of the actin cytoskeleton within dendritic spines. Synaptic degeneration is restricted to excitatory synapses, spares presynaptic structures, and results in decrements in functional synaptic transmission. Pharmacological inhibition of any one of the steps in the signaling cascade, as well as expression of a dominant-negative form of p38 MAPK, block PrPSc-induced spine degeneration. Moreover, p38 MAPK inhibitors actually reverse the degenerative process after it has already begun. We also show that, while PrPC mediates the synaptotoxic effects of both PrPSc and the Alzheimer's Aβ peptide in this system, the two species activate distinct signaling pathways. Taken together, our results provide powerful insights into the biology of prion neurotoxicity, they identify new, druggable therapeutic targets, and they allow comparison of prion synaptotoxic pathways with those involved in other neurodegenerative diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.ppat.1007283

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 79

  1. A Aguzzi, 2004, Mammalian prion biology: one century of evolving concepts, Cell, 116, 313, 10.1016/S0092-8674(03)01031-6 · DOI · Paper page
  2. DA Kocisko, 1994, Cell-free formation of protease-resistant prion protein, Nature, 370, 471, 10.1038/370471a0 · DOI · Paper page
  3. RA Bessen, 1995, Non-genetic propagation of strain-specific properties of scrapie prion protein, Nature, 375, 698, 10.1038/375698a0 · DOI · Paper page
  4. H Büeler, 1993, Mice devoid of PrP are resistant to scrapie, Cell, 73, 1339, 10.1016/0092-8674(93)90360-3 · DOI · Paper page
  5. SB Prusiner, 1993, Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies, Proc Natl Acad Sci USA, 90, 10608, 10.1073/pnas.90.22.10608 · DOI · Paper page
  6. H Büeler, 1992, Normal development and behavior of mice lacking the neuronal cell-surface PrP protein, Nature, 356, 577, 10.1038/356577a0 · DOI · Paper page
  7. S Brandner, 1996, Normal host prion protein necessary for scrapie-induced neurotoxicity, Nature, 379, 339, 10.1038/379339a0 · DOI · Paper page
  8. G Mallucci, 2003, Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis, Science, 302, 871, 10.1126/science.1090187 · DOI · Paper page
  9. MK Sandberg, 2011, Prion propagation and toxicity in vivo occur in two distinct mechanistic phases, Nature, 470, 540, 10.1038/nature09768 · DOI · Paper page
  10. MK Sandberg, 2014, Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked, Nat Commun, 5, 4347, 10.1038/ncomms5347 · DOI · Paper page
  11. E Biasini, 2012, Prion protein at the crossroads of physiology and disease, Trends Neurosci, 35, 92, 10.1016/j.tins.2011.10.002 · DOI · Paper page
  12. CM Henstridge, 2016, Synaptic pathology: A shared mechanism in neurological disease., Ageing Res Rev, 28, 72, 10.1016/j.arr.2016.04.005 · DOI · Paper page
  13. PV Belichenko, 2000, Dendritic and synaptic alterations of hippocampal pyramidal neurones in scrapie-infected mice, Neuropathol Appl Neurobiol, 26, 143, 10.1046/j.1365-2990.2000.026002143.x · DOI · Paper page
  14. JL Campeau, 2013, Early increase and late decrease of purkinje cell dendritic spine density in prion-infected organotypic mouse cerebellar cultures, PLoS One, 8, e81776, 10.1371/journal.pone.0081776 · DOI
  15. J Clinton, 1993, Synaptic degeneration is the primary neuropathological feature in prion disease: a preliminary study, Neuroreport, 4, 65, 10.1097/00001756-199301000-00017 · DOI · Paper page
  16. C Cunningham, 2003, Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease, Eur J Neurosci, 17, 2147, 10.1046/j.1460-9568.2003.02662.x · DOI · Paper page
  17. M Jeffrey, 2000, Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus, Neuropathol Appl Neurobiol, 26, 41, 10.1046/j.1365-2990.2000.00216.x · DOI · Paper page
  18. GG Kovacs, 2005, Subcellular localization of disease-associated prion protein in the human brain, Am J Pathol, 166, 287, 10.1016/S0002-9440(10)62252-3 · DOI
  19. M Fuhrmann, 2007, Dendritic pathology in prion disease starts at the synaptic spine, J Neurosci, 27, 6224, 10.1523/JNEUROSCI.5062-06.2007 · DOI · Paper page
  20. GR Mallucci, 2009, Prion neurodegeneration: starts and stops at the synapse, Prion, 3, 195, 10.4161/pri.3.4.9981 · DOI
  21. C Fang, 2016, A neuronal culture system to detect prion synaptotoxicity, PLoS Pathog, 12, e1005623, 10.1371/journal.ppat.1005623 · DOI
  22. C Sala, 2014, Dendritic spines: the locus of structural and functional plasticity, Physiol Rev, 94, 141, 10.1152/physrev.00012.2013 · DOI · Paper page
  23. AE King, 2016, Excitotoxicity in ALS: Overstimulation, or overreaction, Exp Neurol, 275, 162, 10.1016/j.expneurol.2015.09.019 · DOI · Paper page
  24. MD Sepers, 2014, Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease, Drug Discov Today, 19, 990, 10.1016/j.drudis.2014.02.006 · DOI
  25. J Lewerenz, 2015, Chronic glutamate toxicity in neurodegenerative diseases-What is the evidence?, Front Neurosci, 9, 469, 10.3389/fnins.2015.00469 · DOI · Paper page
  26. DK Morrison, 2012, MAP kinase pathways, Cold Spring Harb Perspect Biol, 4, 10.1101/cshperspect.a011254 · DOI · Paper page
  27. T Zarubin, 2005, Activation and signaling of the p38 MAP kinase pathway, Cell Res, 15, 11, 10.1038/sj.cr.7290257 · DOI · Paper page
  28. A Cuenda, 1997, Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38), EMBO J, 16, 295, 10.1093/emboj/16.2.295 · DOI · Paper page
  29. ES Wong, 2009, p38MAPK controls expression of multiple cell cycle inhibitors and islet proliferation with advancing age, Dev Cell, 17, 142, 10.1016/j.devcel.2009.05.009 · DOI
  30. RH Adams, 2000, Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development, Mol Cell, 6, 109, 10.1016/S1097-2765(05)00014-6 · DOI · Paper page
  31. A Cuadrado, 2010, Mechanisms and functions of p38 MAPK signalling, Biochem J, 429, 403, 10.1042/BJ20100323 · DOI · Paper page
  32. A Shiryaev, 2010, Mitogen-activated protein kinase p38 and MK2, MK3 and MK5: menage a trois or menage a quatre?, Cell Signal, 22, 1185, 10.1016/j.cellsig.2010.03.002 · DOI
  33. D Dingar, 2010, Characterization of the expression and regulation of MK5 in the murine ventricular myocardium, Cell Signal, 22, 1063, 10.1016/j.cellsig.2010.02.009 · DOI
  34. B Caughey, 1992, Potent inhibition of scrapie-associated PrP accumulation by Congo red, J Neurochem, 59, 768, 10.1111/j.1471-4159.1992.tb09437.x · DOI · Paper page
  35. B Caughey, 1993, Congo red inhibition of scrapie agent replication, J Virol, 67, 6270, 10.1128/JVI.67.10.6270-6272.1993 · DOI
  36. I Hlushchenko, 2016, Dendritic spine actin dynamics in neuronal maturation and synaptic plasticity, Cytoskeleton, 73, 435, 10.1002/cm.21280 · DOI · Paper page
  37. G Lukinavicius, 2014, Fluorogenic probes for live-cell imaging of the cytoskeleton, Nat Methods, 11, 731, 10.1038/nmeth.2972 · DOI · Paper page
  38. JA Moreno, 2012, Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration, Nature, 485, 507, 10.1038/nature11058 · DOI · Paper page
  39. M Halliday, 2015, Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity, Cell Death Dis, 6, e1672, 10.1038/cddis.2015.49 · DOI · Paper page
  40. C Sidrauski, 2015, Pharmacological dimerization and activation of the exchange factor eIF2B antagonizes the integrated stress response, Elife, 4, e07314, 10.7554/eLife.07314 · DOI · Paper page
  41. Y Sekine, 2015, Stress responses. Mutations in a translation initiation factor identify the target of a memory-enhancing compound, Science, 348, 1027, 10.1126/science.aaa6986 · DOI · Paper page
  42. BR Fluharty, 2013, An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo, J Biol Chem, 288, 7857, 10.1074/jbc.M112.423954 · DOI · Paper page
  43. S Chen, 2010, Interaction between human prion protein and amyloid-β (Aβ) oligomers: the role of N-terminal residues, J Biol Chem, 285, 26377, 10.1074/jbc.M110.145516 · DOI · Paper page
  44. E Bove-Fenderson, 2017, Cellular prion protein targets amyloid-β fibril ends via its C-terminal domain to prevent elongation, J Biol Chem, 292, 16858, 10.1074/jbc.M117.789990 · DOI
  45. JW Um, 2012, Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons, Nat Neurosci, 15, 1227, 10.1038/nn.3178 · DOI · Paper page
  46. LT Haas, 2017, Silent allosteric modulation of mGluR5 maintains glutamate signaling while rescuing Alzheimer's mouse phenotypes, Cell Rep, 20, 76, 10.1016/j.celrep.2017.06.023 · DOI · Paper page
  47. FH Beraldo, 2011, Metabotropic glutamate receptors transduce signals for neurite outgrowth after binding of the prion protein to laminin γ1 chain, FASEB J, 25, 265, 10.1096/fj.10-161653 · DOI · Paper page
  48. G Schmitt-Ulms, 2001, Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein, J Mol Biol, 314, 1209, 10.1006/jmbi.2000.5183 · DOI · Paper page
  49. DR Taylor, 2007, The low-density lipoprotein receptor-related protein 1 (LRP1) mediates the endocytosis of the cellular prion protein, Biochem J, 402, 17, 10.1042/BJ20061736 · DOI · Paper page
  50. SA Black, 2014, Cellular prion protein and NMDA receptor modulation: protecting against excitotoxicity, Front Cell Dev Biol, 2, 45, 10.3389/fcell.2014.00045 · DOI
  51. L Gasperini, 2015, Prion protein and copper cooperatively protect neurons by modulating NMDA receptor through S-nitrosylation, Antioxid Redox Signal, 22, 772, 10.1089/ars.2014.6032 · DOI · Paper page
  52. A Majer, 2012, Early mechanisms of pathobiology are revealed by transcriptional temporal dynamics in hippocampal CA1 neurons of prion infected mice, PLoS Pathog, 8, e1003002, 10.1371/journal.ppat.1003002 · DOI · Paper page
  53. SH Lee, 2000, Constitutive activity and differential localization of p38α and p38β MAPKs in adult mouse brain, J Neurosci Res, 60, 623, 10.1002/(SICI)1097-4547(20000601)60:5<623::AID-JNR7>3.0.CO;2-4 · DOI · Paper page
  54. GM Thomas, 2004, MAPK cascade signalling and synaptic plasticity, Nat Rev Neurosci, 5, 173, 10.1038/nrn1346 · DOI · Paper page
  55. KL Eales, 2014, The MK2/3 cascade regulates AMPAR trafficking and cognitive flexibility, Nat Commun, 5, 4701, 10.1038/ncomms5701 · DOI
  56. R Raveendran, 2009, Phosphorylation status of the NR2B subunit of NMDA receptor regulates its interaction with calcium/calmodulin-dependent protein kinase II, J Neurochem, 110, 92, 10.1111/j.1471-4159.2009.06108.x · DOI · Paper page
  57. US Herrmann, 2015, Prion infections and anti-PrP antibodies trigger converging neurotoxic pathways, PLoS Pathog, 11, e1004662, 10.1371/journal.ppat.1004662 · DOI · Paper page
  58. HP Lee, 2005, Activation of mitogen-activated protein kinases in hamster brains infected with 263K scrapie agent, J Neurochem, 95, 584, 10.1111/j.1471-4159.2005.03429.x · DOI
  59. B Puig, 2016, Secretory pathway retention of mutant prion protein induces p38-MAPK activation and lethal disease in mice, Sci Rep, 6, 24970, 10.1038/srep24970 · DOI
  60. V Villa, 2006, Characterization of the proapoptotic intracellular mechanisms induced by a toxic conformer of the recombinant human prion protein fragment 90–231, Ann NY Acad Sci, 1090, 276, 10.1196/annals.1378.030 · doi:10.1196/annals.1378.030
  61. M Pietri, 2013, PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases, Nat Med, 19, 1124, 10.1038/nm.3302 · DOI
  62. D Goniotaki, 2017, Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity, PLoS Pathog, 13, e1006733, 10.1371/journal.ppat.1006733 · DOI
  63. WEG Müller, 1993, Cytoprotective effect of NMDA receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell cultures, Eur J Pharmacol, 246, 261, 10.1016/0922-4106(93)90040-G · DOI · Paper page
  64. S Korte, 2003, Modulation of L-type voltage-gated calcium channels by recombinant prion protein, J Neurochem, 87, 1037, 10.1046/j.1471-4159.2003.02080.x · DOI
  65. CR Trevitt, 2006, A systematic review of prion therapeutics in experimental models, Brain, 129, 2241, 10.1093/brain/awl150 · DOI · Paper page
  66. CD Orru, 2014, A test for Creutzfeldt-Jakob disease using nasal brushings, N Engl J Med, 371, 519, 10.1056/NEJMoa1315200 · DOI · Paper page
  67. F Moda, 2014, Prions in the urine of patients with variant Creutzfeldt-Jakob disease, N Engl J Med, 371, 530, 10.1056/NEJMoa1404401 · DOI · Paper page
  68. AS Borders, 2008, The p38α mitogen-activated protein kinase as a central nervous system drug discovery target, BMC Neurosci, 9, S12, 10.1186/1471-2202-9-S2-S12 · DOI · Paper page
  69. S Yasuda, 2011, p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases, Cent Nerv Syst Agents Med Chem, 11, 45, 10.2174/187152411794961040 · DOI · Paper page
  70. L Munoz, 2010, Targeting p38 MAPK pathway for the treatment of Alzheimer's disease, Neuropharmacology, 58, 561, 10.1016/j.neuropharm.2009.11.010 · DOI · Paper page
  71. DG Ferreira, 2017, α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B, Nat Neurosci, 20, 1569, 10.1038/nn.4648 · DOI · Paper page
  72. S Kaech, 2006, Culturing hippocampal neurons, Nat Protoc, 1, 2406, 10.1038/nprot.2006.356 · DOI · Paper page
  73. CJ Miranda, 2012, Aging brain microenvironment decreases hippocampal neurogenesis through Wnt-mediated survivin signaling, Aging cell, 11, 542, 10.1111/j.1474-9726.2012.00816.x · DOI · Paper page
  74. DP Srivastava, 2011, Analysis of dendritic spine morphology in cultured CNS neurons, J Vis Exp, e2794
  75. W Shen, 2006, Activity-induced rapid synaptic maturation mediated by presynaptic cdc42 signaling, Neuron, 50, 401, 10.1016/j.neuron.2006.03.017 · DOI
  76. E Biasini, 2008, Multiple biochemical similarities between infectious and non-infectious aggregates of a prion protein carrying an octapeptide insertion, J Neurochem, 104, 1293, 10.1111/j.1471-4159.2007.05082.x · DOI
  77. JA Turnbaugh, 2012, The N-terminal, polybasic region of PrPC dictates the efficiency of prion propagation by binding to PrPSc, J Neurosci, 32, 8817, 10.1523/JNEUROSCI.1103-12.2012 · DOI
  78. JG Safar, 2002, Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice, Nat Biotechnol, 20, 1147, 10.1038/nbt748 · DOI · Paper page
  79. WL Klein, 2002, Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets, Neurochem Int, 41, 345, 10.1016/S0197-0186(02)00050-5 · DOI · Paper page

Cited by

Metadata

Authors
Fang, C., Wu, B., Le, N. T. T., Imberdis, T., Mercer, R. C. C., & Harris, D. A.
Venue
PLOS Pathogens
Published
2018-09-20
Volume
14
Issue
9
Pages
e1007283
ISSN
  • 1553-7366 (ISSN-L)
  • 1553-7374
OpenAlex
W2891577239
Cited by
72
References
21
FWCI
2.28
Type
journal article
Language
en
Open access
gold
Funders
National Institutes of Health (R01 NS065244)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.